With no established treatments for VC-associated cutaneous manifestations, the efficacy of standard therapeutic agents—such as calcium channel blockers, α-1-adrenergic receptor antagonists, angiotensin receptor blockers, topical nitrates, fluoxetine, phosphodiesterase inhibitors, endothelin-1 receptor antagonists, or antiplatelet agents for Raynaud symptoms and methotrexate, mycophenolate mofetil, cyclophosphamide, D-penicillamine, intravenous immunoglobulin, hematopoietic stem cell transplantation, tocilizumab and rituximab for VC-induced SS—remains uncertain [44,45]. The gene discussed is EDNRA; the disease is synovial sarcoma.